Literature DB >> 29155353

Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline.

Victor Chedid1, Priya Vijayvargiya1, Michael Camilleri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29155353      PMCID： PMC5816691          DOI： 10.1016/j.cgh.2017.11.025

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  17 in total

1.  Treatment of diarrhea in irritable colon, including preliminary observations with a new antidiarrheal agent, diphenoxylate hydrochloride (Lomotil).

Authors:  A M KASICH
Journal:  Am J Gastroenterol       Date:  1961-01       Impact factor: 10.864

Review 2.  Agonist-specific regulation of the delta-opioid receptor.

Authors:  Eva V Varga; Edita Navratilova; Dagmar Stropova; Janelle Jambrosic; William R Roeske; Henry I Yamamura
Journal:  Life Sci       Date:  2004-12-24       Impact factor: 5.037

Review 3.  Irritable Bowel Syndrome.

Authors:  Alexander C Ford; Brian E Lacy; Nicholas J Talley
Journal:  N Engl J Med       Date:  2017-06-29       Impact factor: 91.245

Review 4.  Peripheral mechanisms in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

5.  Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.

Authors:  Leonard S Dove; Anthony Lembo; Charles W Randall; Ronald Fogel; David Andrae; J Michael Davenport; Gail McIntyre; June S Almenoff; Paul S Covington
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

6.  Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study.

Authors:  B Lavö; M Stenstam; A L Nielsen
Journal:  Scand J Gastroenterol Suppl       Date:  1987

7.  Loperamide treatment of the irritable bowel syndrome.

Authors:  N Hovdenak
Journal:  Scand J Gastroenterol Suppl       Date:  1987

Review 8.  Drug-induced acute pancreatitis: an evidence-based review.

Authors:  Nison Badalov; Robin Baradarian; Kadirawel Iswara; Jianjun Li; William Steinberg; Scott Tenner
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03-28       Impact factor: 11.382

9.  A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome.

Authors:  P S Efskind; T Bernklev; M H Vatn
Journal:  Scand J Gastroenterol       Date:  1996-05       Impact factor: 2.423

Review 10.  Sphincter of Oddi Function and Risk Factors for Dysfunction.

Authors:  Elham Afghani; Simon K Lo; Paul S Covington; Brooks D Cash; Stephen J Pandol
Journal:  Front Nutr       Date:  2017-01-30
View more
  7 in total

Review 1.  Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.

Authors:  Edoardo Savarino; Fabiana Zingone; Brigida Barberio; Giovanni Marasco; Filiz Akyuz; Hale Akpinar; Oana Barboi; Giorgia Bodini; Serhat Bor; Giuseppe Chiarioni; Gheorghe Cristian; Maura Corsetti; Antonio Di Sabatino; Anca Mirela Dimitriu; Vasile Drug; Dan L Dumitrascu; Alexander C Ford; Goran Hauser; Radislav Nakov; Nisha Patel; Daniel Pohl; Cătălin Sfarti; Jordi Serra; Magnus Simrén; Alina Suciu; Jan Tack; Murat Toruner; Julian Walters; Cesare Cremon; Giovanni Barbara
Journal:  United European Gastroenterol J       Date:  2022-06-13       Impact factor: 6.866

Review 2.  Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders?

Authors:  Maura Corsetti; Jasper Pannemans; Peter Whorwell
Journal:  F1000Res       Date:  2019-03-05

Review 3.  Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.

Authors:  Rebecca Liu; Kyle Staller
Journal:  Drug Des Devel Ther       Date:  2020-04-09       Impact factor: 4.162

4.  Adverse outcomes associated with the treatment of Toxoplasma infections.

Authors:  Ahmed M Shammaa; Thomas G Powell; Imaan Benmerzouga
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

5.  Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change.

Authors:  Brooks D Cash; Brian E Lacy; Cheryl Watton; Philip S Schoenfeld; Darren Weissman
Journal:  Therap Adv Gastroenterol       Date:  2021-04-10       Impact factor: 4.409

6.  Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.

Authors:  Susan Park; So Hyun Choi; Yun-Kyoung Song; Jin-Won Kwon
Journal:  JMIR Public Health Surveill       Date:  2022-01-04

7.  Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.

Authors:  Nayoung Han; Jung Mi Oh; In-Wha Kim
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.